- Arvinas Inc to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program Call TranscriptDec 06, 2023
- Arvinas Inc To Host ESMO Data Presentation Call TranscriptOct 22, 2023
- Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Arvinas Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Arvinas Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Arvinas Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Arvinas Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Arvinas Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Arvinas Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 23, 2023
- Arvinas, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 01:30 PM TranscriptJan 11, 2023
- Arvinas Inc SABCS Event TranscriptNov 22, 2022
- Arvinas Inc at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- Arvinas Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Arvinas Inc at Citi BioPharma Conference TranscriptSep 08, 2022
- Arvinas Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Arvinas Inc at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Arvinas Inc to Discuss the Phase 1 Dose Escalation Data and Interim Data from the Phase 2 ARDENT Trial TranscriptFeb 17, 2022
- Arvinas Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Arvinas Inc ARV-471 Program Update Call TranscriptDec 10, 2021
- Arvinas Inc and Pfizer Inc Announce ARV-471 Collaboration- Conference Call TranscriptJul 22, 2021
- Arvinas Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Arvinas Inc at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Arvinas Inc ASCO Data Conference Call TranscriptMay 29, 2020
- Arvinas Inc Conference Call TranscriptOct 23, 2019
Arvinas Inc at Jefferies Healthcare Conference Transcript
Still good morning. All right, good morning, everyone. Day two of our Jefferies Healthcare Conference. I hope everyone's enjoying themselves. I have -- for those who don't know me, my name is Akash Tewari. I'm a pharma and biotech analyst here, and I have the pleasure of hosting Arvinas, which as of just in an AK this morning, published some new data on their AR degrader franchise, and this is certainly a part of your company that I think doesn't get enough attention right now, and I could critique myself. I don't think I've given it enough attention.
So maybe I'll hand it off to Ron to give some brief introductory remarks and go over some of the data.
Yeah. Certainly. Yeah. And just to say that John Houston, who's a CEO, will probably be walking in any minute, and yeah. So well -- and Ian Taylor will be joining us as well as a Chief Scientific Officer.
Yeah, so we're really excited to have this opportunity to disclose our initial data on 766,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)